BRAF and melanoma: Despite the success of anti-BRAF therapy in melanoma, data from randomized clinical trials are lacking for targeted therapy against BRAF mutations—typically the V600E variant—in pancreatic adenocarcinoma, which is associated with a poor prognosis under traditional cytotoxic chemotherapy.